22302-65-4

Usage

InChI:InChI=1/C12H11NO2/c1-8(14)13-11-6-2-5-10-9(11)4-3-7-12(10)15/h2-7,15H,1H3,(H,13,14)

Upstream product

• 83-55-6 5-amino-1-naphthol 
• 108-24-7 acetic anhydride 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 51687-73-1 N-(5-methoxynaphthalen-1-yl)acetamide 
• 6271-81-4 5-methoxynaphthalen-1-ylamine 
• 61735-51-1 1-iodo-5-methoxynaphthalene 
• 481-42-5 5-hydroxy-2-methyl-1,4-naphthoquinone 

Relevant academic research and scientific papers

Green photochemistry: Solarchemical synthesis of 5-amido-1,4- naphthoquinones

Dye sensitized photooxygenations of 5-amido-1-naphthols were investigated with artificial light and sunlight, and the corresponding 5-amido-1,4- naphthoquinones were isolated in moderate to excellent yields. Under sunny conditions the yields were higher for almost all cases studied. The energy demand of the equipment used was determined, revealing significant energy savings for solar exposures.

Pyrazines and Pyridines and Derivatives Thereof as Therapeutic Compounds

The present invention pertains to certain pyrazines and pyridines, and derivatives thereof, which, inter alia, inhibit RAF (e.g., B RAF) activity, inhibit cell proliferation, treat cancer, etc., and more particularly to compounds of the formulae: (I) wherein: Q is independently —N═ or —CH═; one of RP2 and RP3 is independently a group of the formula -J1-L1-Z; wherein: if Q is —N═, then -J1-L1-Z is independently: —NH-Z; —O-Z; or S-Z; if Q is —CH═, then -J1-L1-Z is independently: —NH—(CH2)n-Z, wherein n is independently 0 or 1; —O-Z; or —S-Z; Z is independently: C6-14 carboaryl, C5-14 heteroaryl, C3-12carbocyclic, C3-12 heterocyclic; and is independently unsubstituted or substituted; the other of RP2 and RP3 is independently —H, —NHRN1, or —NHC(═O)RN2; wherein: RN1, if present, is independently —H or aliphatic saturated C1-4alkyl; RN2, if present, is independently —H or aliphatic saturated C1-4alkyl; one of RP5 and RP6 is independently a group of the formula —W—Y; wherein: W is independently: a covalent bond; —NRN4—, —O—, —S—, —C(═O)—, —CH2—; —NRN4—CH2—, —O—CH2—, —S—CH2—, —C(═O)—CH2—, —(CH2)2—; —CH2—NRN4—, —CH2—O—, —CH2—S—, or —CH2—C(═O)—; wherein RN4, if present, is independently —H or aliphatic saturated C1-4alkyl; Y is independently: C6-14carboaryl, C5-14heteroaryl, C3-12carbocyclic, C3-12heterocyclic; and is independently unsubstituted or substituted; the other of RP5 and RP6 is independently —H; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, N-oxides, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, e.g., both in vitro and in vivo, to inhibit RAF (e.g., B-RAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and conditions that are ameliorated by the inhibition of RAF, RTK, etc., proliferative conditions such as cancer (e.g., colorectal cancer, melanoma), etc.

Cationic couplers and their use for oxidation dyeing

The subject of the invention is novel compounds derived from naphth-1-ol comprising at least one cationic group, their use as coupler for the oxidation dyeing of keratinous fibres, compositions for the oxidation dyeing of keratinous fibres, and in particular human keratinous fibres such as hair, containing them in combination with at least one oxidation base, as well as methods of oxidation dyeing using them.

Synthesis and β1-, β2-adrenergic receptor binding studies of 4-acylamino-substituted phenoxypropanolamine and 5-acylamino-substituted naphthyloxypropanolamine derivatives

The object of this study was to investigate the β-adrenergic receptor binding affinity of 4-acylaminophenoxypropanolamine (10-15) and 5-acylaminonaphthyloxypropanolamine (21-24) derivatives, which were prepared from 4-amino-phenol (5) and 5-amino-1-naphthol (16), respectively. The in vitro β1- and β2-adrenergic receptor binding affinities of the newly synthesized compounds were assessed in turkey erythrocyte membrane (β1) and lung homogenates of rats (β2). The binding affinities were compared with that of propranolol (3) (propranolol hydrochloride, CAS 318-98-9). The compound N-[5-(3-tert-butylamino-2-hydroxy-propoxy)-naphthalen-1-yl]-acetamide (22) has β-adrenergic receptor affinity comparable with that of propranolol and shows selectivity to β1-adrenergic receptors.